Tosylation of (±)-1-[trans-4-hydroxy-3,3-bis(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2(1H),4(3H)-dione (1) and (±)-1-[cis-4-hydroxy-3,3-bis(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2(1H),4(3H)-dione (2) and treatment of the obtained 1-(1R*,3R*,4S*)- 4-hydroxy-3-(hydroxymethyl)-3-[(tosyloxy)methyl]cyclopentyl}-5-methylpyrimidine- 2(1H),4(3H)-dione (6) and 1-(1R*,3S*,4R*)-4-hydroxy-3-(hydroxymethyl)-3-[(tosyloxy)- methyl]cyclopentyl}-5-methylpyrimidine-2(1H),4(3H)-dione (9) with methanolic sodium methoxide gave 1-[(1R*,4S*,6S*)-4-hydroxymethyl-2-oxabicyclo[3.2.0]hept-6-yl]-5-methylpyrimidine-2(1H),4(3H)-dione (7) and 1-[(1R*,4S*,6R*)-4-hydroxymethyl-2-oxabicyclo[3.2.0]hept-6-yl]-5-methylpyrimidine-2(1H),4(3H)-dione (10), respectively. Treatment of (±)-1-cis-4-mesyloxy-3,3-bis[(trityloxy)methyl]cyclopentyl}-5-methylpyrimidine-2(1H),4(3H)-dione (11), which was prepared from 2 by tritylation and mesylation, with 1,8-diazabicyclo[5.4.0]undec-7-ene in dimethylformamide afforded after deprotection (±)-1-[4,4-bis(hydroxymethyl)cyclopent-2-en-1-yl]-5-methylpyrimidine-2(1H),4(3H)-dione (14). Hydrogen- ation of 14 led to (±)-1-[3,3-bis(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2(1H),4(3H)- dione (15). (±)-1-trans-4-Mesyloxy-3,3-bis[(trityloxy)methyl]cyclopentyl}-5-methylpyrimidine- 2(1H),4(3H)-dione (17), which was prepared from 1, was converted to (1R*,9R*)-6-methyl-5-oxo-11,11-bis(trityloxymethyl)-2-oxa-4,8-diazatricyclo[7.2.1.03,8]dodec-3,6-diene (18). The compound 18 was deprotected and heated with lithium azide in dimethylformamide to give (±)-1-[trans-4-azido-3,3-bis(hydroxymethyl)cyclopentyl]-5-methylpyrimidine-2(1H),4(3H)-dione (21).
对(±)-1-[
trans-
4-羟基-3,3-双(羟甲基)环戊基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
1)和(±)-1-[
cis-
4-羟基-3,3-双(羟甲基)环戊基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
2)进行甲
苯磺酸化反应,得到1-(1
R*,3
R*,4
S*)-
4-羟基-3-(羟甲基)-3-[(对
甲苯磺酰氧)甲基]环戊基}-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
6)和1-(1
R*,3
S*,4
R*)-
4-羟基-3-(羟甲基)-3-[(对
甲苯磺酰氧)甲基]环戊基}-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
9)。将得到的化合物与
甲醇钠甲醇溶液反应,得到1-[(1
R*,4
S*,6
S*)-4-羟甲基-2-氧杂双环[3.2.0]庚-6-基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
7)和1-[(1
R*,4
S*,6
R*)-4-羟甲基-2-氧杂双环[3.2.0]庚-6-基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
10)。将(±)-1-
cis-4-甲磺氧基-3,3-双[(三苯甲氧基)甲基]环戊基}-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
11)与
1,8-二氮杂双环[5.4.0]十一碳-7-烯在二甲基甲酰胺中反应,去保护后得到(±)-1-[4,4-双(羟甲基)环戊-2-烯基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
14)。对
14进行氢化反应,得到(±)-1-[3,3-双(羟甲基)环戊基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
15)。从
1制备(±)-1-
trans-4-甲磺氧基-3,3-双[(三苯甲氧基)甲基]环戊基}-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
17),并将其转化为(1
R*,9
R*)-6-甲基-5-氧代-11,11-双(三苯甲氧基甲基)-2-氧杂四环[7.2.1.0
3,8]十二碳-3,6-二烯 (
18)。将化合物
18去保护并在二甲基甲酰胺中与
锂叠氮化合物加热反应,得到(±)-1-[
trans-4-
叠氮基-3,3-双(羟甲基)环戊基]-5-
甲基嘧啶-2(1
H),4(3
H)-二酮 (
21)。